Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy

摘要: Objective Patients infected with HIV-1 are at high risk of developing Epstein–Barr virus (EBV)-associated lymphoproliferative disorders. This study evaluated the impact highly active antiretroviral therapy (HAART) on EBV infection. Methods To measure content in peripheral blood lymphocytes (PBL) and plasma, we set up a quantitative analysis using real-time PCR. latent membrane protein 1 (LMP1) expression was determined by reverse transcriptase-PCR. Results levels were 33 HIV-1- EBV-coinfected patients start HAART, during therapy. At baseline, PBL samples ranged from 8 to 14 532 copies/μg DNA. transiently increased nine out 17 whom plasmaviraemia declined undetectable (virological response) CD4 cell counts (immunological response), while they remained fairly stable or decreased other eight virological immunological responders, seven who showed response only. Of interest, significant increase load observed five an but lack suppression HAART. accompanied detection both LMP1 transcripts DNA paralleled immunoglobulin levels, marker B-cell stimulation. Conclusions These findings suggest that immune reconstitution HAART without reduction replication may stimulation number EBV-infected B cells.